Solid Biosciences (SLDB) Total Current Liabilities (2017 - 2024)
Solid Biosciences (SLDB) has disclosed Total Current Liabilities for 8 consecutive years, with $22.9 million as the latest value for Q3 2024.
- Quarterly Total Current Liabilities rose 44.5% to $22.9 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $22.9 million through Sep 2024, up 44.5% year-over-year, with the annual reading at $14.5 million for FY2023, 35.5% down from the prior year.
- Total Current Liabilities hit $22.9 million in Q3 2024 for Solid Biosciences, up from $14.7 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $24.5 million in Q4 2020 to a low of $12.9 million in Q1 2020.
- Historically, Total Current Liabilities has averaged $18.8 million across 5 years, with a median of $20.3 million in 2023.
- Biggest five-year swings in Total Current Liabilities: surged 77.24% in 2021 and later tumbled 35.5% in 2023.
- Year by year, Total Current Liabilities stood at $24.5 million in 2020, then decreased by 3.59% to $23.6 million in 2021, then decreased by 4.63% to $22.5 million in 2022, then crashed by 35.5% to $14.5 million in 2023, then soared by 57.43% to $22.9 million in 2024.
- Business Quant data shows Total Current Liabilities for SLDB at $22.9 million in Q3 2024, $14.7 million in Q2 2024, and $14.3 million in Q1 2024.